

# Darren R Feldman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8341688/publications.pdf>

Version: 2024-02-01

169  
papers

10,508  
citations

50276

46  
h-index

37204

96  
g-index

172  
all docs

172  
docs citations

172  
times ranked

14932  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments. <i>Ear and Hearing</i> , 2022, 43, 794-807.	2.1	13
2	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
3	Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. <i>European Urology</i> , 2022, 81, 570-573.	1.9	22
4	Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Nonâ€“Clear-Cell Renal Cell Carcinoma and Genomic Correlates. <i>Journal of Clinical Oncology</i> , 2022, 40, 2333-2341.	1.6	72
5	Pharmacogenomics of <sc>cisplatinâ€“induced</sc> neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. <i>Cancer Medicine</i> , 2022, 11, 2801-2816.	2.8	14
6	A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors. <i>Investigational New Drugs</i> , 2022, 40, 1087-1094.	2.6	7
7	Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>JCO Precision Oncology</i> , 2022, , .	3.0	3
8	Testicular Germ Cell Tumors Acquire Cisplatin Resistance by Rebalancing the Usage of DNA Repair Pathways. <i>Cancers</i> , 2021, 13, 787.	3.7	15
9	Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors. <i>Oncologist</i> , 2021, 26, 483-491.	3.7	8
10	Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 430-438.	0.7	14
11	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydrataseâ€“Deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2910-2919.	7.0	45
12	Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1129-1138.	2.5	4
13	Thoracic Metastasectomy in Germ Cell Tumor Patients Treated With First-line Versus Salvage Therapy. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1141-1149.	1.3	4
14	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. <i>Genome Medicine</i> , 2021, 13, 96.	8.2	26
15	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021, 19, 1510-1521.	3.4	20
16	Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors. <i>Investigational New Drugs</i> , 2021, 39, 1656-1663.	2.6	5
17	Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 438.e1-438.e6.	1.2	11
18	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1553-1562.	1.6	83

#	ARTICLE	IF	CITATIONS
19	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1563-1574.	1.6	108
20	Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e178-e183.	1.9	2
21	Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell Tumors. <i>Annals of Surgery</i> , 2021, 274, e1099-e1107.	4.2	9
22	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. <i>European Urology Oncology</i> , 2021, 4, 993-1000.	5.4	16
23	The experience of hearing loss in adult survivors of childhood and young adult cancer: A qualitative study. <i>Cancer</i> , 2020, 126, 1776-1783.	4.1	8
24	Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance). <i>Cancer</i> , 2020, 126, 5311-5318.	4.1	13
25	RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors. <i>Urology</i> , 2020, 144, 111-116.	1.0	5
26	Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. <i>Cancer</i> , 2020, 126, 5247-5255.	4.1	22
27	Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa022.	2.9	11
28	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. <i>JCO Precision Oncology</i> , 2020, 4, 1307-1320.	3.0	9
29	Solid and Hematologic Neoplasms After Testicular Cancer: A US Population-Based Study of 24%900 Survivors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa017.	2.9	12
30	Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1332-1337.	1.6	11
31	Reply to L.H. Einhorn et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 3074-3075.	1.6	0
32	DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. , 2020, 8, e000230.		37
33	Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. <i>BMC Urology</i> , 2020, 20, 84.	1.4	12
34	Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. <i>Clinical Cancer Research</i> , 2020, 26, 6550-6558.	7.0	9
35	Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. <i>Journal of Clinical Investigation</i> , 2020, 130, 6668-6676.	8.2	28
36	Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. <i>Oncologist</i> , 2019, 24, 1497-1501.	3.7	22

#	ARTICLE	IF	CITATIONS
37	Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 5913-5924.	7.0	16
38	Altering the Natural History of Surgical Relapse in Testicular Cancer: Suboptimal Surgery and Pneumoperitoneum. <i>European Urology</i> , 2019, 76, 612-614.	1.9	7
39	Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 268-274.e1.	1.9	29
40	Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 2329-2337.	1.6	17
41	High-dose radiation therapy is needed for intracranial control and long-term survival in patients with non-seminomatous germ cell tumor brain metastases. <i>Journal of Neuro-Oncology</i> , 2019, 142, 523-528.	2.9	4
42	Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms. <i>Clinical Cancer Research</i> , 2019, 25, 4104-4116.	7.0	27
43	Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e678-e688.	1.9	41
44	Comprehensive Genomic Analysis of Metastatic Non-“Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets. <i>JCO Precision Oncology</i> , 2019, 3, 1-18.	3.0	7
45	Datasets for the reporting of neoplasia of the testis: recommendations from the International Collaboration on Cancer Reporting. <i>Histopathology</i> , 2019, 74, 171-183.	2.9	13
46	Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience.. <i>Urology</i> , 2019, 124, 174-178.	1.0	6
47	Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2019, 5, 642-649.	3.1	40
48	Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 12-17.	1.6	25
49	Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 459-468.	4.9	13
50	Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1529-1554.	4.9	174
51	Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. <i>Urology</i> , 2018, 114, 133-138.	1.0	12
52	Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases. <i>Oncologist</i> , 2018, 23, 316-323.	3.7	34
53	Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. <i>Urology</i> , 2018, 118, 114-118.	1.0	7
54	Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. <i>European Journal of Cancer</i> , 2018, 94, 115-125.	2.8	280

#	ARTICLE	IF	CITATIONS
55	Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e761-e769.	1.9	28
56	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2018, 4, 986-994.	3.1	29
57	State-of-the-Art Management of Germ Cell Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 319-323.	3.8	14
58	Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in Time to Start Backing Out. <i>Journal of Clinical Oncology</i> , 2018, 36, 837-840.	1.6	15
59	Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1505-1512.	1.6	95
60	Testicular cancer. <i>Nature Reviews Disease Primers</i> , 2018, 4, 29.	30.5	299
61	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1228.	7.1	132
62	Conventional-Dose versus High-Dose Chemotherapy for Relapsed Germ Cell Tumors. <i>Advances in Urology</i> , 2018, 2018, 1-7.	1.3	16
63	Hearing Loss in Adult Survivors of Childhood Cancer Treated with Radiotherapy. <i>Children</i> , 2018, 5, 59.	1.5	10
64	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018, 6, 758-765.	3.4	89
65	Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 257-265.	4.9	24
66	Integrated Molecular Characterization of Testicular Germ Cell Tumors. <i>Cell Reports</i> , 2018, 23, 3392-3406.	6.4	324
67	Hematologic Malignancies Arising in Patients with Germ Cell Tumors: Secondary Somatic Differentiation of Hematopoietic Malignancies from Germ Cell Precursors. <i>Blood</i> , 2018, 132, 87-87.	1.4	3
68	Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity. <i>Clinical Cancer Research</i> , 2017, 23, 3325-3333.	7.0	65
69	Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 532.e7-532.e13.	1.6	25
70	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	30.7	2,473
71	Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5757-5768.	7.0	63
72	Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e987-e994.	1.9	39

#	ARTICLE	IF	CITATIONS
73	Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. <i>Urology</i> , 2017, 103, 154-160.	1.0	12
74	Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. <i>Journal of Urology</i> , 2017, 197, 391-397.	0.4	10
75	Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. <i>European Urology Focus</i> , 2017, 3, 590-598.	3.1	31
76	Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , 2017, 3, 421-427.	3.1	43
77	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 591-597.	1.6	584
78	Cisplatin Therapy Does Not Worsen Renal Function in Severe Antenatal Bartter Syndrome. <i>Case Reports in Nephrology and Dialysis</i> , 2017, 7, 49-54.	0.6	0
79	Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. <i>Journal of Clinical Oncology</i> , 2017, 35, 3525-3528.	1.6	56
80	Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1211-1222.	1.6	86
81	Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2712-2720.	1.6	197
82	Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience. <i>Urology</i> , 2016, 95, 128-131.	1.0	6
83	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 2478-2483.	1.6	31
84	Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Nonâ€“Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3846-3853.	1.6	69
85	Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 4000-4007.	1.6	147
86	Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis. <i>European Urology</i> , 2016, 70, 1082-1083.	1.9	38
87	Are Some Cases of Somatic Type Malignancy Potentially Avoidable?. <i>Journal of Urology</i> , 2016, 196, 11-13.	0.4	0
88	A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2016, 21, 787-788d.	3.7	84
89	Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 56-62.	1.9	7
90	Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Optionsâ€“An Analysis From the Global Germ Cell Cancer Group. <i>Journal of Clinical Oncology</i> , 2016, 34, 345-351.	1.6	69

#	ARTICLE	IF	CITATIONS
91	Risk of Vascular Toxicity with Platinum Based Chemotherapy in Elderly Patients with Bladder Cancer. <i>Journal of Urology</i> , 2016, 195, 33-40.	0.4	23
92	Variation in protein-coding sequence and the genetic basis of cisplatin-induced toxicities among testicular cancer survivors (TCS) in the Platinum Study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1537-1537.	1.6	1
93	Genome-wide association study of cisplatin-induced peripheral neuropathy (CIPN) in testicular cancer survivors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4543-4543.	1.6	2
94	The Management of Advanced Germ Cell Tumors in 2016: The Memorial Sloan Kettering Approach. <i>Oncology</i> , 2016, 30, 653-64.	0.5	5
95	Update in germ cell tumours. <i>Current Opinion in Oncology</i> , 2015, 27, 177-184.	2.4	13
96	Reply to L.C. Pagliaro et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 2327-2328.	1.6	2
97	Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 453-460.	1.9	5
98	Development of a risk stratification system to guide treatment for female germ cell tumors. <i>Gynecologic Oncology</i> , 2015, 138, 566-572.	1.4	34
99	Late Relapse of Testicular Germ Cell Tumors. <i>Urologic Clinics of North America</i> , 2015, 42, 359-368.	1.8	31
100	Salvage high-dose chemotherapy for germ cell tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 355-362.	1.6	12
101	Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. <i>Journal of Clinical Oncology</i> , 2015, 33, 3018-3028.	1.6	63
102	Interrogation of a Context-Specific Transcription Factor Network Identifies Novel Regulators of Pluripotency. <i>Stem Cells</i> , 2015, 33, 367-377.	3.2	32
103	Safety and Efficacy of Targeted Therapy for Renal Cell Carcinoma With Brain Metastasis. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 59-66.	1.9	32
104	Rates of Teratoma and Viable Cancer at Post-Chemotherapy Retroperitoneal Lymph Node Dissection after Induction Chemotherapy for Good Risk Nonseminomatous Germ Cell Tumors. <i>Journal of Urology</i> , 2015, 193, 513-518.	0.4	20
105	Microwave Ablation (MWA) for the Treatment of a Solitary, Chemorefractory Testicular Cancer Liver Metastasis. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 488-493.	2.0	0
106	Association of genomic alterations with cisplatin resistance (cisR) in advanced germ cell tumors (aGCT).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4510-4510.	1.6	3
107	Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach. <i>PLoS ONE</i> , 2015, 10, e0142846.	2.5	18
108	Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 811-822.	4.9	9



#	ARTICLE	IF	CITATIONS
109	Epidemiology, Biology, and Genetics of Adult Male Germ Cell Tumors. , 2015, , 431-450.		0
110	Chemotherapy-Induced Peripheral Neurotoxicity and Ototoxicity: New Paradigms for Translational Genomics. Journal of the National Cancer Institute, 2014, 106, dju044-dju044.	6.3	94
111	Treatment Options for Stage I Nonseminoma. Journal of Clinical Oncology, 2014, 32, 3797-3800.	1.6	15
112	Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. Annals of Oncology, 2014, 25, 663-668.	1.2	71
113	The role of high-dose chemotherapy in the management of germ cell tumors. Current Opinion in Oncology, 2014, 26, 284-293.	2.4	3
114	Presence of Somatic Mutations within <i>PIK3CA</i> , <i>AKT</i> , <i>RAS</i> , and <i>FGFR3</i> but not <i>BRAF</i> in Cisplatin-Resistant Germ Cell Tumors. Clinical Cancer Research, 2014, 20, 3712-3720.	7.0	88
115	Editorial Comment. Urology, 2014, 84, 890-891.	1.0	2
116	Clinical Outcomes of Local and Metastatic Testicular Sex Cord-Stromal Tumors. Journal of Urology, 2014, 192, 415-419.	0.4	49
117	Long-term mortality in patients with germ cell tumors: Effect of primary cancer site on cause of death. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 26.e9-26.e15.	1.6	23
118	Beyond Stage I Germ Cell Tumors: Current Status Regarding Treatment and Long-Term Toxicities. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e180-e190.	3.8	9
119	Fertility preservation strategies for male patients with cancer. Nature Reviews Urology, 2013, 10, 463-472.	3.8	42
120	A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. Investigational New Drugs, 2013, 31, 1016-1022.	2.6	41
121	Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2013, 11, 297-302.	1.9	46
122	The conundrum of clinical trials in adult germ-cell tumours. Lancet Oncology, The, 2013, 14, 14-15.	10.7	4
123	Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. Cancer, 2013, 119, 2574-2581.	4.1	30
124	Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors. International Journal of Developmental Biology, 2013, 57, 273-280.	0.6	64
125	Phase I/II study of paclitaxel plus ifosfamide (TI) followed by high-dose paclitaxel, ifosfamide, and carboplatin (TIC) with autologous stem cell transplant (ASCT) for salvage treatment of germ cell tumors (GCT).. Journal of Clinical Oncology, 2013, 31, 4534-4534.	1.6	1
126	Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).. Journal of Clinical Oncology, 2013, 31, 336-336.	1.6	6



#	ARTICLE	IF	CITATIONS
127	Late Cardiovascular Toxicity Following Chemotherapy for Germ Cell Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 537-544.	4.9	56
128	Body Mass Index Is Associated With Higher Lymph Node Counts During Retroperitoneal Lymph Node Dissection. <i>Urology</i> , 2012, 79, 361-364.	1.0	16
129	Clinical Impact of Residual Extraretroperitoneal Masses in Patients With Advanced Nonseminomatous Germ Cell Testicular Cancer. <i>Urology</i> , 2012, 79, 156-159.	1.0	28
130	Outcomes in Patients With Clinical Stage III NSGCT Who Achieve Complete Clinical Response to Chemotherapy at Extraretroperitoneal Disease Site. <i>Urology</i> , 2012, 79, 1079-1084.	1.0	5
131	The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis. <i>European Journal of Cancer</i> , 2012, 48, 340-346.	2.8	49
132	Rare De Novo Germline Copy-Number Variation in Testicular Cancer. <i>American Journal of Human Genetics</i> , 2012, 91, 379-383.	6.2	21
133	Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2012, 118, 1868-1876.	4.1	109
134	Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. <i>Cancer</i> , 2012, 118, 5078-5083.	4.1	33
135	The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. <i>Investigational New Drugs</i> , 2012, 30, 1773-1781.	2.6	50
136	Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design. <i>Cancer</i> , 2012, 118, 981-986.	4.1	50
137	Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. <i>Investigational New Drugs</i> , 2012, 30, 335-340.	2.6	79
138	Reduced Proficiency in Homologous Recombination Underlies the High Sensitivity of Embryonal Carcinoma Testicular Germ Cell Tumors to Cisplatin and Poly (ADP-Ribose) Polymerase Inhibition. <i>PLoS ONE</i> , 2012, 7, e51563.	2.5	78
139	A Review of Second-line Chemotherapy and Prognostic Models for Disseminated Germ Cell Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 557-576.	2.2	16
140	Contemporary Lymph Node Counts During Primary Retroperitoneal Lymph Node Dissection. <i>Urology</i> , 2011, 77, 368-372.	1.0	14
141	Outcomes After Resection of Postchemotherapy Residual Neck Mass in Patients With Germ Cell Tumors—An Update. <i>Urology</i> , 2011, 77, 655-659.	1.0	10
142	Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial. <i>Journal of Cancer</i> , 2011, 2, 374-377.	2.5	55
143	Sarcomatoid-variant Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 454-459.	1.3	91
144	Paclitaxel, Ifosfamide and Cisplatin (TIP) Beyond Its Original Indication for Salvage Treatment of Germ Cell Tumors. <i>Oncology Research and Treatment</i> , 2011, 34, 410-411.	1.2	3

#	ARTICLE	IF	CITATIONS
145	High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis. <i>Journal of Clinical Oncology</i> , 2011, 29, 3466-3473.	1.6	369
146	High-dose chemotherapy and stem cell transplantation for advanced testicular cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1093-1105.	2.4	16
147	Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities. <i>Oncologist</i> , 2011, 16, 543-553.	3.7	74
148	Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , 2010, 28, 523-528.	2.6	66
149	Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. <i>Cancer</i> , 2010, 116, 5243-5250.	4.1	25
150	Reply to L.H. Einhorn et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e740-e740.	1.6	1
151	Testicular Cancer Survivorship: Research Strategies and Recommendations. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1114-1130.	6.3	260
152	TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis. <i>Journal of Clinical Oncology</i> , 2010, 28, 1706-1713.	1.6	192
153	Reply to B.I. Rini et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e286-e287.	1.6	4
154	Natural immunity to pluripotency antigen OCT4 in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 8718-8723.	7.1	78
155	The approach to the patient with synchronous bilateral germ cell tumors: a lesson in oncologic prioritization. <i>Oncology</i> , 2010, 24, 761-3.	0.5	5
156	Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1432-1439.	1.6	298
157	Identification and Validation of a Gene Expression Signature That Predicts Outcome in Adult Men With Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, 5240-5247.	1.6	70
158	Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 7405-7411.	7.0	44
159	Good-risk-advanced germ cell tumors: historical perspective and current standards of care. <i>World Journal of Urology</i> , 2009, 27, 463-470.	2.2	10
160	Phase II Trial of Pegylated Interferon- $\beta$ 2b in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2008, 6, 25-30.	1.9	20
161	Treatment of stage I seminoma: is it time to change your practice?. <i>Journal of Hematology and Oncology</i> , 2008, 1, 22.	17.0	7
162	Infectious Complications from High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Metastatic Germ Cell Tumors. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 595-600.	2.0	6

#	ARTICLE	IF	CITATIONS
163	Medical Treatment of Advanced Testicular Cancer. JAMA - Journal of the American Medical Association, 2008, 299, 672.	7.4	307
164	Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors?. Nature Reviews Urology, 2008, 5, 78-79.	1.4	1
165	Curing germ cell tumors after failure of high-dose chemotherapy: progress through clinical trials. Nature Clinical Practice Oncology, 2007, 4, 508-509.	4.3	0
166	Re: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. Journal of the National Cancer Institute, 2007, 99, 974-975.	6.3	26
167	Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Investigational New Drugs, 2007, 25, 487-490.	2.6	21
168	Novel targets and therapies for metastatic renal cell carcinoma. Oncology, 2006, 20, 1745-53; discussion 1756.	0.5	9
169	Associations of Body Fat Distribution and Cardiometabolic Risk of Testicular Cancer Survivors after Cisplatin-Based Chemotherapy. JNCI Cancer Spectrum, 0, , .	2.9	2